Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Aligos Therapeutics
Dosing of ALG-020572 (ASO) in healthy volunteers underway Enrollment in first 2 STOPS cohorts (120, 200 mg) complete; enrollment in 3rd cohort (400 mg) underway Clinical trial application (CTA)...
Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021
October 28, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021
October 14, 2021 16:58 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
October 11, 2021 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
September 20, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET
|
Aligos Therapeutics
Raised $83.6 million in gross proceeds from common stock offeringSTOPS™ and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoingClinical trial application filed for...
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
July 29, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
June 30, 2021 22:08 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common...
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
June 28, 2021 16:10 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of...
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
June 21, 2021 08:00 ET
|
Aligos Therapeutics
-First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients-Presentations include nonclinical data from 3 other CHB programs ...